Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765817 · ClinicalTrials.gov registry record · Phase 3
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT00765817 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 261 participants.
The verdict
NCT00765817, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
Interventions
- DRUG placebo
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765817
The ClinicalTrials.gov registry entry for NCT00765817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00765817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765817 about?
NCT00765817 is a clinical study titled "Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus". This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
What is the current status of trial NCT00765817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2008-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00765817?
The interventions under investigation include: placebo (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00765817?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.